← Leaderboards
Jerrold M Olefsky
University Of California San Diego
$29,583,289
Attributed
$29,583,289
Total exposure
29
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.2M · FY2005–17$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$47,521,404 · 30
By mechanism
P30$19,084,851 · 2
R37$6,091,149 · 1
R01$5,934,549 · 4
P01$4,269,224 · 3
U54$3,871,340 · 3
T32$3,001,114 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Jeffrey T Chang$4,144,512
- R Jeffrey Chang$12,222,781
- Samuel S Yen$0
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectNoninsulin Dependent Diabetes MellitusInsulin Sensitivity /ResistanceInsulinGlucose MetabolismHuman Therapy EvaluationInsulin ResistanceLeadSignal TransductionDiabetes MellitusHormone Regulation /Control MechanismInflammationKnockout MiceBaseDiabetes Mellitus TherapyMolecularAdipocytesReceptorDrug Screening /EvaluationTroglitazonePhenotypePlayObesity
Grant awards (177)
Diabetes Research Center (DRC)$1,943,511
P30 · FY2017 · DK · contact PI
Effects of Fractalkine on Beta Cell Function$387,500
R01 · FY2017 · DK · contact PI
MECHANISM OF GPR120 SIGNALING TO ANTII-NFLAMMATORY/INSULIN SENSITIZING PATHWAYS$348,752
P01 · FY2017 · DK · contact PI
ADMINISTRATIVE CORE$231,606
P30 · FY2017 · DK · contact PI
Diabetes Research Center (DRC)$1,943,511
P30 · FY2016 · DK · contact PI
Aipocyte/Macrophage Crosstalk in the Etiology of Insulin Resistance.$420,042
P01 · FY2016 · DK · contact PI
Effects of Fractalkine on Beta Cell Function$387,500
R01 · FY2016 · DK · contact PI
MECHANISM OF GPR120 SIGNALING TO ANTII-NFLAMMATORY/INSULIN SENSITIZING PATHWAYS$348,750
P01 · FY2016 · DK · contact PI
ADMINISTRATIVE CORE$231,606
P30 · FY2016 · DK · contact PI
Diabetes Research Center (DRC)$1,943,511
P30 · FY2015 · DK · contact PI
Aipocyte/Macrophage Crosstalk in the Etiology of Insulin Resistance.$420,042
P01 · FY2015 · DK · contact PI
Effects of Fractalkine on Beta Cell Function$387,500
R01 · FY2015 · DK · contact PI
MECHANISM OF GPR120 SIGNALING TO ANTII-NFLAMMATORY/INSULIN SENSITIZING PATHWAYS$348,750
P01 · FY2015 · DK · contact PI
Role of Inflammation and Insulin Resistance in Mouse Models of Breast Cancer$251,661
U54 · FY2015 · CA · contact PI
ADMINISTRATIVE CORE$231,606
P30 · FY2015 · DK · contact PI
Diabetes Research Center (DRC)$1,957,260
P30 · FY2014 · DK · contact PI
Aipocyte/Macrophage Crosstalk in the Etiology of Insulin Resistance.$420,043
P01 · FY2014 · DK · contact PI
Effects of Fractalkine on Beta Cell Function$387,500
R01 · FY2014 · DK · contact PI
MECHANISM OF GPR120 SIGNALING TO ANTII-NFLAMMATORY/INSULIN SENSITIZING PATHWAYS$348,750
P01 · FY2014 · DK · contact PI
ADMINISTRATIVE CORE$233,514
P30 · FY2014 · DK · contact PI
Role of Inflammation and Insulin Resistance in Mouse Models of Breast Cancer$225,924
U54 · FY2014 · CA · contact PI
Diabetes Research Center (DRC)$1,860,233
P30 · FY2013 · DK · contact PI
Insulin Receptors and the Glucose Transport System$536,472
R01 · FY2013 · DK · contact PI
Aipocyte/Macrophage Crosstalk in the Etiology of Insulin Resistance.$407,676
P01 · FY2013 · DK · contact PI
PROJECT 2 - METABOLIC CONTROL OF REPRODUCTION$373,398
U54 · FY2013 · HD · contact PI
MECHANISM OF GPR120 SIGNALING TO ANTII-NFLAMMATORY/INSULIN SENSITIZING PATHWAYS$348,750
P01 · FY2013 · DK · contact PI
Role of Inflammation and Insulin Resistance in Mouse Models of Breast Cancer$229,321
U54 · FY2013 · CA · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$226,522
T32 · FY2013 · DK · contact PI
ADMINISTRATIVE CORE$218,404
P30 · FY2013 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$32,651
T32 · FY2013 · DK · contact PI
Diabetes Endocrinology Research Center$1,402,785
P30 · FY2012 · DK · contact PI
Insulin Receptors and the Glucose Transport System$555,929
R01 · FY2012 · DK · contact PI
Aipocyte/Macrophage Crosstalk in the Etiology of Insulin Resistance.$419,816
P01 · FY2012 · DK · contact PI
PROJECT 2 - METABOLIC CONTROL OF REPRODUCTION$385,471
U54 · FY2012 · HD · contact PI
Role of Inflammation and Insulin Resistance in Mouse Models of Breast Cancer$250,231
U54 · FY2012 · CA · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$176,544
T32 · FY2012 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$16,325
T32 · FY2012 · DK · contact PI
Diabetes Endocrinology Research Center$1,402,785
P30 · FY2011 · DK · contact PI
Molecular Mechanisms of Inflammation, Steatosis and Hepatic Insulin Resistance$745,195
R24 · FY2011 · DK · contact PI
Insulin Receptors and the Glucose Transport System$554,136
R01 · FY2011 · DK · contact PI
PROJECT 2 - METABOLIC CONTROL OF REPRODUCTION$383,851
U54 · FY2011 · HD · contact PI
Role of Inflammation and Insulin Resistance in Mouse Models of Breast Cancer$259,672
U54 · FY2011 · CA · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$200,019
T32 · FY2011 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$16,092
T32 · FY2011 · DK · contact PI
Diabetes Endocrinology Research Center$1,402,785
P30 · FY2010 · DK · contact PI
Molecular Mechanisms of Inflammation, Steatosis and Hepatic Insulin Resistance$753,204
R24 · FY2010 · DK · contact PI
Insulin Receptors and the Glucose Transport System$561,638
R01 · FY2010 · DK · contact PI
PROJECT 2 - METABOLIC CONTROL OF REPRODUCTION$402,096
U54 · FY2010 · HD · contact PI
Diabetes Endocrinology Research Center$231,750
P30 · FY2010 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$228,919
T32 · FY2010 · DK · contact PI
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$93,656
R37 · FY2010 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$15,865
T32 · FY2010 · DK · contact PI
Diabetes Endocrinology Research Center$1,402,785
P30 · FY2009 · DK · contact PI
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$699,781
R37 · FY2009 · DK · contact PI
Diabetes Endocrinology Research Center$546,930
P30 · FY2009 · DK · contact PI
Diabetes Endocrinology Research Center$431,750
P30 · FY2009 · DK · contact PI
PROJECT 2 - METABOLIC CONTROL OF REPRODUCTION$394,277
U54 · FY2009 · HD · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$200,728
T32 · FY2009 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$15,755
T32 · FY2009 · DK · contact PI
Diabetes Endocrinology Research Center$1,468,519
P30 · FY2008 · DK · contact PI
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$682,045
R37 · FY2008 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$188,083
T32 · FY2008 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$15,645
T32 · FY2008 · DK · contact PI
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$678,387
R37 · FY2007 · DK · contact PI
Functional Char. of Pro-Inflammatory Pathways Influencing Insulin Influencing Ins$437,853
P01 · FY2007 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$225,250
T32 · FY2007 · DK · contact PI
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$681,078
R37 · FY2006 · DK · contact PI
Estrogens and Insulin Resistance in Women$371,070
R01 · FY2006 · DK · contact PI
TRAINING PROGRAM IN DIABETES RESEARCH$225,998
T32 · FY2006 · DK · contact PI
PIOGLITAZONE THERAPY FOR INFLAMMATORY PATHWAY COMPONENT OF INSULIN RESISTANCE$149,258
M01 · FY2006 · RR · contact PI
EFFECT OF COMBINATION OF PPAR GAMMA AND ALPHA AGONISTS ON INSULIN SENSITIVITY$15,767
M01 · FY2006 · RR · contact PI
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$1,577
M01 · FY2006 · RR · contact PI
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$700,331
R37 · FY2005 · DK
PIOGLITAZONE THERAPY FOR INFLAMMATORY PATHWAY COMPONENT OF INSULIN RESISTANCE$434,089
M01 · FY2005 · RR
Estrogens and Insulin Resistance in Women$380,000
R01 · FY2005 · DK
EFFECT OF COMBINATION OF PPAR GAMMA AND ALPHA AGONISTS ON INSULIN SENSITIVITY$272,298
M01 · FY2005 · RR
TRAINING PROGRAM IN DIABETES RESEARCH$224,378
T32 · FY2005 · DK
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$8,548
M01 · FY2005 · RR
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$542,029
R37 · FY2004 · DK
Estrogens and Insulin Resistance in Women$380,000
R01 · FY2004 · DK
PPAR gamma /alpha Agonist Effect on Insulin Sensitivity$259,639
M01 · FY2004 · RR
Carbohydrate Diet Effect on Plasma Glucose/Insulin/Lipid$238,985
M01 · FY2004 · RR
TRAINING PROGRAM IN DIABETES RESEARCH$224,119
T32 · FY2004 · DK
Pioglitazone for Inflammatory Pathway in Insulin Resista$109,167
M01 · FY2004 · RR
Estrogen Effects in Insulin Target and Granulosa Cells$100,000
R55 · FY2004 · DK
Gender Differences In Susceptibility To Fatty Acid Induced Insulin Resistance$19,473
M01 · FY2004 · RR
Evaluation of Unusual Forms of Insulin Resistance$12,981
M01 · FY2004 · RR
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$526,412
R37 · FY2003 · DK
Estrogens and Insulin Resistance in Women$380,000
R01 · FY2003 · DK
TRAINING PROGRAM IN DIABETES RESEARCH$210,524
T32 · FY2003 · DK
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$511,080
R37 · FY2002 · DK
PRIMARY PREVENTION TRIAL (DPT-2)$421,092
U01 · FY2002 · DK
Estrogens and Insulin Resistance in Women$380,000
R01 · FY2002 · DK
TRAINING PROGRAM IN DIABETES RESEARCH$208,960
T32 · FY2002 · DK
GNRH SIGNALING IN THE GONADOTROPE$174,159
U54 · FY2002 · HD
GNRH SIGNALING IN THE GONADOTROPE$174,159
U54 · FY2002 · HD
SAFETY, EFFICACY &PHARMACOKINETICS OF ORAL FLUASTERONE IN NIDDM$0
M01 · FY2002 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2002 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2002 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2002 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2002 · RR
MRI OF POSTERIOR FOSSA NEUROVASCULAR RELATIONSHIPS$0
M01 · FY2002 · RR
MRI OF POSTERIOR FOSSA NEUROVASCULAR RELATIONSHIPS$0
M01 · FY2002 · RR
MRI OF POSTERIOR FOSSA NEUROVASCULAR RELATIONSHIPS$0
M01 · FY2002 · RR
MRI OF POSTERIOR FOSSA NEUROVASCULAR RELATIONSHIPS$0
M01 · FY2002 · RR
EFFECT OF SOMAVERT ON INSULIN SENSITIVITY IN TYPE II DIABETES$0
M01 · FY2002 · RR
EFFECT OF SOMAVERT ON INSULIN SENSITIVITY IN TYPE II DIABETES$0
M01 · FY2002 · RR
EFFECT OF SOMAVERT ON INSULIN SENSITIVITY IN TYPE II DIABETES$0
M01 · FY2002 · RR
EFFECT OF SOMAVERT ON INSULIN SENSITIVITY IN TYPE II DIABETES$0
M01 · FY2002 · RR
PPAR RECEPTORS IN MECHANISM OF TROGLITAZONE IN INSULIN RESISTANCE$0
M01 · FY2002 · RR
PPAR RECEPTORS IN MECHANISM OF TROGLITAZONE IN INSULIN RESISTANCE$0
M01 · FY2002 · RR
PPAR RECEPTORS IN MECHANISM OF TROGLITAZONE IN INSULIN RESISTANCE$0
M01 · FY2002 · RR
PPAR RECEPTORS IN MECHANISM OF TROGLITAZONE IN INSULIN RESISTANCE$0
M01 · FY2002 · RR
MECHANISMS OF INSULIN RESISTANCE IN NIDDM$0
M01 · FY2002 · RR
MECHANISMS OF INSULIN RESISTANCE IN NIDDM$0
M01 · FY2002 · RR
MECHANISMS OF INSULIN RESISTANCE IN NIDDM$0
M01 · FY2002 · RR
MECHANISMS OF INSULIN RESISTANCE IN NIDDM$0
M01 · FY2002 · RR
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$0
M01 · FY2002 · RR
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$0
M01 · FY2002 · RR
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$0
M01 · FY2002 · RR
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$0
M01 · FY2002 · RR
TROGLITAZONE STUDY IN EARLY TYPE II DIABETES$0
M01 · FY2002 · RR
TROGLITAZONE STUDY IN EARLY TYPE II DIABETES$0
M01 · FY2002 · RR
TROGLITAZONE STUDY IN EARLY TYPE II DIABETES$0
M01 · FY2002 · RR
TROGLITAZONE STUDY IN EARLY TYPE II DIABETES$0
M01 · FY2002 · RR
SAFETY, EFFICACY &PHARMACOKINETICS OF ORAL FLUASTERONE IN NIDDM$0
M01 · FY2002 · RR
SAFETY, EFFICACY &PHARMACOKINETICS OF ORAL FLUASTERONE IN NIDDM$0
M01 · FY2002 · RR
SAFETY, EFFICACY &PHARMACOKINETICS OF ORAL FLUASTERONE IN NIDDM$0
M01 · FY2002 · RR
PRIMARY PREVENTION TRIAL (DPT-2)$917,852
U01 · FY2001 · DK
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$496,195
R37 · FY2001 · DK
TRAINING PROGRAM IN DIABETES RESEARCH$176,788
T32 · FY2001 · DK
GNRH SIGNALING IN THE GONADOTROPE$174,159
U54 · FY2001 · HD
TROGLITAZONE STUDY IN EARLY TYPE II DIABETES$0
M01 · FY2001 · RR
SAFETY, EFFICACY &PHARMACOKINETICS OF ORAL FLUASTERONE IN NIDDM$0
M01 · FY2001 · RR
SAFETY, EFFICACY &PHARMACOKINETICS OF ORAL FLUASTERONE IN NIDDM$0
M01 · FY2001 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2001 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2001 · RR
MRI OF POSTERIOR FOSSA NEUROVASCULAR RELATIONSHIPS$0
M01 · FY2001 · RR
MRI OF POSTERIOR FOSSA NEUROVASCULAR RELATIONSHIPS$0
M01 · FY2001 · RR
EFFECT OF SOMAVERT ON INSULIN SENSITIVITY IN TYPE II DIABETES$0
M01 · FY2001 · RR
EFFECT OF SOMAVERT ON INSULIN SENSITIVITY IN TYPE II DIABETES$0
M01 · FY2001 · RR
PPAR RECEPTORS IN MECHANISM OF TROGLITAZONE IN INSULIN RESISTANCE$0
M01 · FY2001 · RR
PPAR RECEPTORS IN MECHANISM OF TROGLITAZONE IN INSULIN RESISTANCE$0
M01 · FY2001 · RR
MECHANISMS OF INSULIN RESISTANCE IN NIDDM$0
M01 · FY2001 · RR
MECHANISMS OF INSULIN RESISTANCE IN NIDDM$0
M01 · FY2001 · RR
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$0
M01 · FY2001 · RR
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$0
M01 · FY2001 · RR
TROGLITAZONE STUDY IN EARLY TYPE II DIABETES$0
M01 · FY2001 · RR
PRIMARY PREVENTION TRIAL (DPT-2)$810,052
U01 · FY2000 · DK
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEM$480,155
R37 · FY2000 · DK
MECHANISMS OF INSULIN RESISTANCE IN MAN$285,304
R01 · FY2000 · DK
GNRH SIGNALING IN THE GONADOTROPE$192,961
U54 · FY2000 · HD
TRAINING PROGRAM IN DIABETES RESEARCH$171,949
T32 · FY2000 · DK
TROGLITAZONE STUDY IN EARLY TYPE II DIABETES$0
M01 · FY2000 · RR
TROGLITAZONE STUDY IN EARLY TYPE II DIABETES$0
M01 · FY2000 · RR
TROGLITAZONE STUDY IN EARLY TYPE II DIABETES$0
M01 · FY2000 · RR
SAFETY, EFFICACY &PHARMACOKINETICS OF ORAL FLUASTERONE IN NIDDM$0
M01 · FY2000 · RR
SAFETY, EFFICACY &PHARMACOKINETICS OF ORAL FLUASTERONE IN NIDDM$0
M01 · FY2000 · RR
SAFETY, EFFICACY &PHARMACOKINETICS OF ORAL FLUASTERONE IN NIDDM$0
M01 · FY2000 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2000 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2000 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2000 · RR
MRI OF POSTERIOR FOSSA NEUROVASCULAR RELATIONSHIPS$0
M01 · FY2000 · RR
MRI OF POSTERIOR FOSSA NEUROVASCULAR RELATIONSHIPS$0
M01 · FY2000 · RR
MRI OF POSTERIOR FOSSA NEUROVASCULAR RELATIONSHIPS$0
M01 · FY2000 · RR
EFFECT OF SOMAVERT ON INSULIN SENSITIVITY IN TYPE II DIABETES$0
M01 · FY2000 · RR
EFFECT OF SOMAVERT ON INSULIN SENSITIVITY IN TYPE II DIABETES$0
M01 · FY2000 · RR
EFFECT OF SOMAVERT ON INSULIN SENSITIVITY IN TYPE II DIABETES$0
M01 · FY2000 · RR
PPAR RECEPTORS IN MECHANISM OF TROGLITAZONE IN INSULIN RESISTANCE$0
M01 · FY2000 · RR
PPAR RECEPTORS IN MECHANISM OF TROGLITAZONE IN INSULIN RESISTANCE$0
M01 · FY2000 · RR
PPAR RECEPTORS IN MECHANISM OF TROGLITAZONE IN INSULIN RESISTANCE$0
M01 · FY2000 · RR
MECHANISMS OF INSULIN RESISTANCE IN NIDDM$0
M01 · FY2000 · RR
MECHANISMS OF INSULIN RESISTANCE IN NIDDM$0
M01 · FY2000 · RR
MECHANISMS OF INSULIN RESISTANCE IN NIDDM$0
M01 · FY2000 · RR
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$0
M01 · FY2000 · RR
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$0
M01 · FY2000 · RR
EVALUATION OF UNUSUAL FORMS OF INSULIN RESISTANCE$0
M01 · FY2000 · RR